Form 4: Incyte CSO Awarded Significant Equity Compensation

Incyte's Chief Strategy Officer, David H. Gardner, received substantial equity awards including restricted stock units, performance shares, and stock options.

Summary

• David H. Gardner, Executive Vice President and Chief Strategy Officer of Incyte Corp (INCY), was granted equity awards on September 22, 2025.
• Awards include 9,429 Restricted Stock Units (RSUs) which will vest 25% annually over four years and are settled one-for-one for common stock.
• He also received 23,573 Performance Shares, which can yield up to 200% of one common share based on Incyte's relative Total Shareholder Return (TSR) over a three-year period starting January 1, 2025, compared to a fixed peer group.
• The performance shares will vest on the third anniversary of the grant date, subject to continued service.
• Additionally, 42,899 Employee Stock Options were granted with an exercise price of $84.73.
• These options will vest in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years, and expire on September 22, 2035.

Sentiment

Score: 7

Explanation: The filing reports routine executive equity compensation, which is generally a positive event as it aligns management incentives with shareholder interests. It does not contain any negative news or unexpected financial results.

Positives

• The equity awards align the interests of the Chief Strategy Officer with those of shareholders, incentivizing long-term company performance and value creation.
• The inclusion of performance shares tied to relative Total Shareholder Return (TSR) encourages competitive performance against industry peers.
• The multi-year vesting schedules for RSUs and stock options promote executive retention and sustained focus on strategic objectives.

Future Outlook

The equity awards are structured with future vesting schedules and performance periods, indicating a long-term incentive for the Chief Strategy Officer. RSUs vest 25% annually over four years, performance shares vest on the third anniversary of the grant date based on a three-year TSR performance period, and stock options vest over approximately four years.

Industry Context

The granting of Restricted Stock Units, performance shares, and stock options is a standard practice in executive compensation within the biotechnology and pharmaceutical industries. These types of awards are commonly used to attract, retain, and motivate key executives by aligning their financial interests with the long-term performance and shareholder value creation of the company.

Comparison to Industry Standards

• The compensation structure, comprising RSUs, performance shares, and stock options, is a common and widely accepted practice for executive incentives in the biotechnology and pharmaceutical sectors.
• Performance shares tied to relative Total Shareholder Return (TSR) against a peer group are a standard mechanism to ensure competitive performance and accountability.
• The filing does not provide specific data on the compensation levels or performance metrics of comparable companies, projects, or global benchmarks to allow for a direct quantitative comparison of the value or terms of these specific awards against industry peers.

Stakeholder Impact

• Shareholders: The equity awards are designed to align the Chief Strategy Officer's long-term interests with shareholder value creation, potentially leading to improved company performance.
• Employees: The awards incentivize key management, which can contribute to overall company stability and strategic direction, indirectly benefiting other employees.

Next Steps

• Continued service of the reporting person with the issuer for vesting of RSUs, performance shares, and stock options.
• Monitoring of Incyte's relative Total Shareholder Return (TSR) against its peer group over the three-year performance period for performance share earning.
• Vesting of RSUs annually over four years from the grant date.
• Vesting of stock options in 37 installments, with 25% after one year and the remainder monthly over three years.

Key Dates

Keywords

Incyte, INCY, Equity Compensation, Restricted Stock Units, Performance Shares, Stock Options, Executive Compensation, Insider Transaction, Form 4